Hepatitis B virus genotype G: Prevalence and impact in patients co-infected with human immunodeficiency virus†
Article first published online: 7 JUL 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Medical Virology
Volume 83, Issue 9, pages 1551–1558, September 2011
How to Cite
Dao, D. Y., Balko, J., Attar, N., Neak, E., Yuan, H.-J., Lee, W. M. and Jain, M. K. (2011), Hepatitis B virus genotype G: Prevalence and impact in patients co-infected with human immunodeficiency virus. J. Med. Virol., 83: 1551–1558. doi: 10.1002/jmv.22160
Financial Disclosure: MKJ—Research Support Roche Pharmaceuticals, TaiMed Biologics, Gilead Sciences, Pfizer Inc., Boehringer Ingelheim, and Vertex Pharmaceuticals. Consulting: Merck Pharmaceuticals. Advisory Board: Vertex Pharmaceuticals, Boehringer Ingelheim. WML—Research Support Bristol Myers Squibb, Merck, Roche Pharmaceuticals, Schering Plough Research Institute, Vertex Pharmaceuticals. Consulting: FoldRx Pharma, Facet Biotech, GSK Pharmaceuticals, Gilead Sciences Inc., Merck, Lilly and Novartis.
- Issue published online: 7 JUL 2011
- Article first published online: 7 JUL 2011
- Manuscript Accepted: 17 MAY 2011
- NIDDK Medical Student Research Training Program (to D.Y.D.). Grant Number: 5-T32DK007745-12
- Jeanne Roberts and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation (to D.Y.D.)
- K23 (partial support to M.K.J.). Grant Number: AI-065630
- HBV genotype;
Relatively little is known about the role of hepatitis B virus (HBV) genotype G (HBV/G) in patients co-infected with human immunodeficiency virus (HIV) and HBV. This study examined the prevalence and association of HBV/G to liver fibrosis in co-infected patients. HBV genotypes were determined by direct sequencing of the HBV surface gene or Trugene® HBV 1.0 assay in 133 patients infected with HIV/HBV. Quantitative testing of HBV-DNA, HBeAg, and anti-HBe were performed using the Versant® HBV 3.0 (for DNA) and the ADVIA®Centaur assay. The non-invasive biomarkers Fib-4 and APRI were used to assess fibrosis stage. Genotype A was present in 103/133 (77%) of the cohort, genotype G in 18/133 (14%) with genotypes D in 8/133, (6%), F 2/133 (1.5%), and H 2/133 (1.5%). Genotype G was associated with hepatitis B e antigen-positivity and high HBV-DNA levels. Additionally, HBV/G (OR 8.25, 95% CI 2.3–29.6, P = 0.0012) was associated with advanced fibrosis score using Fib-4, whereas, being black was not (OR 0.19, 95% CI 0.05–0.07, P = 0.01). HBV/G in this population exhibited a different phenotype than expected for pure G genotypes raising the question of recombination or mixed infections. The frequent finding of HBV/G in co-infected patients and its association with more advanced fibrosis, suggests that this genotype leads to more rapid liver disease progression. Further studies are needed to understand why this genotype occurs more frequently and what impact it has on liver disease progression in patients with HBV/HIV. J. Med. Virol. 83:1551–1558, 2011. © 2011 Wiley-Liss, Inc.